NASDAQ:WVE WAVE Life Sciences (WVE) Stock Price, News & Analysis $6.18 -0.59 (-8.64%) As of 12:07 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About WAVE Life Sciences Stock (NASDAQ:WVE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get WAVE Life Sciences alerts:Sign Up Key Stats Today's Range$6.17▼$6.8150-Day Range$6.20▼$14.0852-Week Range$5.02▼$21.73Volume1.77 million shsAverage Volume4.29 million shsMarket Capitalization$1.19 billionP/E RatioN/ADividend YieldN/APrice Target$27.50Consensus RatingModerate Buy Company Overview WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines. The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications. Several assets are advancing through preclinical research and clinical trials, and WAVE collaborates with biopharmaceutical partners to co-develop selected candidates and expand the reach of its technology into new disease areas. WAVE’s research and development activities are anchored in its laboratories in Cambridge, Massachusetts, where multidisciplinary teams of chemists, biologists and clinical scientists work to translate novel oligonucleotide designs into development candidates. The company also maintains strategic collaborations and research partnerships in North America and Asia, aiming to accelerate global access to its therapies and support regulatory filings in multiple jurisdictions. Founded in 2015, WAVE Life Sciences has built a leadership team with deep expertise in RNA biology, medicinal chemistry and drug development. The company continues to refine its stereopure oligonucleotide platform to address delivery challenges, improve pharmacokinetics and expand its pipeline across a broad range of genetic and rare diseases.AI Generated. May Contain Errors. Read More WAVE Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreWVE MarketRank™: WAVE Life Sciences scored higher than 55% of companies evaluated by MarketBeat, and ranked 478th out of 864 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingWAVE Life Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on no strong buy ratings, 14 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialWAVE Life Sciences has a consensus price target of $27.50, representing about 306.2% upside from its current price of $6.77.Amount of Analyst CoverageWAVE Life Sciences has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about WAVE Life Sciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Earnings GrowthEarnings for WAVE Life Sciences are expected to remain at ($1.16) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of WAVE Life Sciences is -6.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of WAVE Life Sciences is -6.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioWAVE Life Sciences has a P/B Ratio of 2.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about WAVE Life Sciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.48% of the float of WAVE Life Sciences has been sold short.Short Interest Ratio / Days to CoverWAVE Life Sciences has a short interest ratio ("days to cover") of 4.14.Change versus previous monthShort interest in WAVE Life Sciences has recently increased by 25.29%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldWAVE Life Sciences does not currently pay a dividend.Dividend GrowthWAVE Life Sciences does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment0.63 News SentimentWAVE Life Sciences has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for WAVE Life Sciences this week, compared to 6 articles on an average week.Search InterestOnly 19 people have searched for WVE on MarketBeat in the last 30 days. This is a decrease of -21% compared to the previous 30 days.MarketBeat Follows9 people have added WAVE Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, WAVE Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $499,570.00 in company stock.Percentage Held by Insiders24.30% of the stock of WAVE Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.73% of the stock of WAVE Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about WAVE Life Sciences' insider trading history. Receive WVE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for WAVE Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. WVE Stock News HeadlinesWave Life Sciences (WVE) price target decreased by 15.26% to 23.97May 15 at 5:56 PM | msn.comWave Life Sciences to Present at 2026 RBC Capital Markets Global Healthcare ConferenceMay 13, 2026 | globenewswire.comBNZI Update: Zacks Buy Rating Sparks Fresh Momentum!Banzai International (NASDAQ: BNZI) delivered full-year 2025 revenue of $12.2 million, a 169% year-over-year increase, with gross margins expanding to 81.9%. The company was recently upgraded to a Zacks Rank 2 (Buy) as analysts raised earnings estimates materially. A planned acquisition of ConnectAndSell is expected to add roughly $15 million in annual revenue, potentially more than doubling BNZI's current revenue base. With 150,000 customers and a unified AI-first platform, the company is building full-funnel capabilities across marketing and sales.May 18 at 1:00 AM | Huge Alerts (Ad)Growth Investors: Industry Analysts Just Upgraded Their Wave Life Sciences Ltd. (NASDAQ:WVE) Revenue Forecasts By 91%May 8, 2026 | finance.yahoo.comWave Life Sciences: Good Platform, Mixed Clinical Trial Data, HoldMay 7, 2026 | seekingalpha.comCanaccord Genuity Reaffirms Their Buy Rating on Wave Life Sciences (WVE)May 3, 2026 | theglobeandmail.comA Look At Wave Life Sciences (WVE) Valuation After Sharp Year To Date Share Price DeclineMay 3, 2026 | finance.yahoo.comWAVE Life Sciences Ltd (WVE) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...April 29, 2026 | finance.yahoo.comSee More Headlines WVE Stock Analysis - Frequently Asked Questions How have WVE shares performed this year? WAVE Life Sciences' stock was trading at $17.00 at the start of the year. Since then, WVE shares have decreased by 60.2% and is now trading at $6.77. How were WAVE Life Sciences' earnings last quarter? WAVE Life Sciences Ltd. (NASDAQ:WVE) announced its earnings results on Wednesday, April, 29th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.21. The firm earned $38.25 million during the quarter, compared to analysts' expectations of $8.45 million. WAVE Life Sciences had a negative net margin of 255.70% and a negative trailing twelve-month return on equity of 56.76%. Read the conference call transcript. When did WAVE Life Sciences IPO? WAVE Life Sciences (WVE) raised $102 million in an initial public offering (IPO) on Wednesday, November 11th 2015. The company issued 6,375,000 shares at $15.00-$17.00 per share. Who are WAVE Life Sciences' major shareholders? Top institutional shareholders of WAVE Life Sciences include First Light Asset Management LLC (0.96%), Affinity Asset Advisors LLC (0.73%), Emerald Advisers LLC (0.66%) and Pictet Asset Management Holding SA (0.61%). Insiders that own company stock include Ra Capital Management, LP, Plc Gsk, Ken Takanashi, Chandra Vargeese, Paul Bolno, Gregory L Verdine, Kyle Moran, Chris Francis, Heidi L Wagner, Mark Corrigan, Christian O Henry and Adrian Rawcliffe. View institutional ownership trends. How do I buy shares of WAVE Life Sciences? Shares of WVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of WAVE Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that WAVE Life Sciences investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Intel (INTC) and Netflix (NFLX). Company Calendar Last Earnings4/29/2026Today5/18/2026RBC Capital Markets Global Healthcare Conference 20265/20/2026Next Earnings (Estimated)7/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 WVE's financial health is in the Red zone, according to TradeSmith. WVE has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:WVE CIK1631574 Webwww.wavelifesciences.com Phone(656) 236-3388Fax617-949-2901Employees240Year Founded2012Price Target and Rating Average Price Target for WAVE Life Sciences$27.50 High Price Target$43.00 Low Price Target$13.00 Potential Upside/Downside+345.3%Consensus RatingModerate Buy Rating Score (0-4)2.87 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($1.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$204.38 million Net Margins-255.70% Pretax Margin-255.70% Return on Equity-56.76% Return on Assets-42.80% Debt Debt-to-Equity RatioN/A Current Ratio11.26 Quick Ratio11.26 Sales & Book Value Annual Sales$42.73 million Price / Sales27.80 Cash FlowN/A Price / Cash FlowN/A Book Value$3.10 per share Price / Book1.99Miscellaneous Outstanding Shares192,400,000Free Float145,648,000Market Cap$1.19 billion OptionableOptionable Beta-1.32 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:WVE) was last updated on 5/18/2026 by MarketBeat.com Staff. From Our PartnersBNZI Update: Zacks Buy Rating Sparks Fresh Momentum!Banzai International (NASDAQ: BNZI) delivered full-year 2025 revenue of $12.2 million, a 169% year-over-year i...Huge Alerts | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredThis next market event could mean total financial ruin for someA market signal last detected before the Great Depression may be flashing again - and according to Weiss Ratin...Weiss Ratings | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredDistracted Americans set to miss out on quadrillionsTechnology expert and Washington D.C. insider Jeff Brown - who identified Bitcoin, Tesla, and Nvidia early - s...Brownstone Research | SponsoredYour book attachedVeteran trader Bill Poulos is giving away his 'Simple Options Trading For Beginners' book - normally $29.97 - ...Profits Run | SponsoredThe Iran War Just Broke the Gold MarketThe Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged...Behind the Markets | SponsoredBuy this Billion-Dollar AI Bottleneck BreakerVeteran analyst Eric Fry says the AI boom is hitting a wall - power, cooling, land, and raw materials are bott...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding WAVE Life Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share WAVE Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
